Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution

Table 3 Clinical course after TKI discontinuation

Parameter	Data
Follow-up after TKI discontinuation (all patients), months
Median	24
Range	15–97
Molecular relapse
Total	14 (56.0%)
SDMR	9 (47.4%)
UDMR	5 (83.3%)
Time to molecular relapse, months
Median	4
Range	2–9
Time to molecular relapse (SDMR patients), months
Median	5
Range	4–9
Time to molecular relapse (UDMR patients), months
Median	3
Range	2–7
Time to MMR after molecular relapse, months
Median	2
Range	1–10
Time to MR ≥ 4.5 after molecular relapse, months
Median	5
Range	2–10
Response at last follow-up (all patients)
MR^5.0	15 (60%)
MR^4.5	5 (20%)
MR^4.0	2 (8%)
MMR	3 (12%)

TKI, tyrosine kinase inhibitor; SDMR, sustained deep molecular response; UDMR, unsustained deep molecular response; MR^5.0, ≥5-log reduction from IRIS baseline; MR^4.5, ≥4.5-log reduction from IRIS baseline; MR^4.0, ≥4.0-log reduction from IRIS baseline; MMR, major molecular response

ISSN: 1471-2407